Patents Assigned to Henry M. Jackson Foundation for the Advancement of Military Medicine
-
Patent number: 11045462Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.Type: GrantFiled: June 9, 2017Date of Patent: June 29, 2021Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Maria F. Braga, Vassiliki Aroniadou-Anderjaska
-
Publication number: 20210188950Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.Type: ApplicationFiled: August 10, 2020Publication date: June 24, 2021Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Yee-Peng Chan, Christopher C. Broder
-
Publication number: 20210171610Abstract: Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.Type: ApplicationFiled: May 2, 2019Publication date: June 10, 2021Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Masaru Kanekiyo, Michael Gordon Joyce, Wei Bu, Jeffrey I. Cohen, Yaroslav Tsybovsky
-
Patent number: 11007249Abstract: The present invention relates to methods of treating a subject suffering from or at risk of suffering from graft versus host disease (GvHD) comprising administering a therapeutically effective amount of at least one of pregnancy specific glycoprotein 1 (PSG1) or PSG9 to a subject in need thereof.Type: GrantFiled: September 16, 2016Date of Patent: May 18, 2021Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Gabriela Dveksler, Harry Malech
-
Patent number: 10987423Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: December 4, 2020Date of Patent: April 27, 2021Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
-
Patent number: 10968430Abstract: The present invention generally relates to the production of antigen-specific T regulatory cells (Tregs). Such cells can be used in therapy to minimize undesirable immune responses such as those observed in autoimmunity and hemophilia and other diseases as well as in the response to protein therapy for genetic diseases. Methods for producing antigen specific Tregs and conditions for preferential expansion of functionally stable, specific Tregs are also provided.Type: GrantFiled: September 6, 2018Date of Patent: April 6, 2021Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: David W. Scott, Yong Chan Kim
-
Patent number: 10967061Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.Type: GrantFiled: May 10, 2019Date of Patent: April 6, 2021Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
-
Publication number: 20210061875Abstract: Provided herein are compositions comprising engineered CD8+ T cells that express a heterologous T cell receptor (TCR) having specificity for an autoantigen bound to a Major Histocompatibility Complex (MHC) Class II. Also provided are methods for the treatment of an autoimmune disease comprising administering the engineered CD8+ T cells. Also provided are methods for generating engineered CD8+ T cells that express a heterologous MHC Class II TCR, including methods of isolating autoantigen-MHC class II specific TCR for use in engineering CD8+ T cells for treatment.Type: ApplicationFiled: December 28, 2018Publication date: March 4, 2021Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventor: Jason R. LEES
-
Patent number: 10900043Abstract: The present invention relates to compositions and methods for preventing and/or treating bacterial disease (e.g., disease caused by Neisseria sp. such as gonorrhea). In particular, the present invention provides compositions comprising an effective amount of a nucleic acid, wherein such compositions are capable of killing or inhibiting the growth of a Neisseria sp. (e.g., Neisseria gonorrhoeae).Type: GrantFiled: May 14, 2019Date of Patent: January 26, 2021Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Won Jong Kim, María Auxilio Rendón-Espinosa, Magdalene Yh So, Maira Goytia, Ann Jerse, Dustin Higashi
-
Publication number: 20210017540Abstract: Vectors and methods are disclosed for immortalizing mammalian cells by co-expression of v-raf and v-myc proteins. A replication-defective viral vector is used for improved safety. The vector comprises an optional marker gene, and is especially useful for producing an immortalized macrophage by a method that involves contacting the vector with a monocyte, proliferatively growing the monocyte, growing the monocytic cell on a solid surface, and then growing the monocytic cell on a porous surface. An immortalized macrophage is also disclosed.Type: ApplicationFiled: March 19, 2019Publication date: January 21, 2021Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Brian C. Schaefer, Chelsi Beauregard
-
Patent number: 10842856Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: March 5, 2018Date of Patent: November 24, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George E. Peoples, Sathibalan Ponniah
-
Patent number: 10821173Abstract: The present disclosure provides fusion proteins that incorporate unique mechanisms for multimerizing antigens to enhance their immunogenicity. The fusion proteins comprise at least two antigens, or other vaccine related proteins, separated by a linker sequence and an oligomerization domain. When expressed, the fusion protein forms a muKimeric protein complex, This approach can be used to muHimeri?.e a single antigen/protein or to create multimers comprising two or more different antigens/proteins. Also provided are nucleic acids encoding the fusion proteins. Yet another aspect is directed to methods of inducing or suppressing an immune response in a subject by administering to the subject a vaccine composition comprising a fusion protein or nucleic acid encoding the fusion protein, optionally without using an adjuvant.Type: GrantFiled: May 4, 2018Date of Patent: November 3, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: James J. Mond, Clifford M. Snapper, Xinle Cui
-
Patent number: 10799473Abstract: Accelerated senescence has been shown to occur as a primary response to cellular stresses including DNA damaging agents (e.g., ionizing radiation) and is widely believed to be caused by continuous proliferative signaling in the presence of cell cycle arrest. The present disclosure provides a method of reducing cellular senescence in non-cancerous cells following exposure to ionizing radiation. The method comprises administering to a subject before, after, or concurrently with exposure to ionizing radiation an effective amount of a compound that inhibits activation of an insulin-like growth factor receptor (IGF-1R) or a compound that inhibits a protein involved in an IGF-1R induced signaling cascade.Type: GrantFiled: March 3, 2014Date of Patent: October 13, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Regina M Day, Ronald-Allan M Panganiban
-
Publication number: 20200309888Abstract: A method of predicting the resistance of a biological sample to the damaging effects of ionizing radiation applied to the biological sample is described, where the method includes measuring by electron paramagnetic resonance (EPR) spectroscopy the amount of divalent manganese (Mn2+) present in the biological sample; and then determining the resistance of the biological sample to the ionizing radiation based on the measured amount of the divalent manganese.Type: ApplicationFiled: September 28, 2018Publication date: October 1, 2020Applicant: The Henry M. Jackson Foundation for the Advancement of Military MedicineInventors: Michael Daly, Brian Hoffman
-
Patent number: 10786683Abstract: Methods and devices related to wound healing using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5.Type: GrantFiled: February 4, 2016Date of Patent: September 29, 2020Assignees: Nitto Denko Corporation, The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sazzadur Rahman Khan, Sheng Li, Amane Mochizuki, Xingjia Wu, Juanita Josephine Anders
-
Patent number: 10738104Abstract: The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides antibodies or antibody fragments that selectively bind to the F glycoprotein of Hendra or Nipah virus, and pharmaceutical compositions including such antibodies and/or fragments. The invention further provides polynucleotides encoding the antibodies and fragments of the invention and host cells transformed therewith. Additionally, the invention discloses prophylactic, therapeutic, and diagnostic methods employing the antibodies, fragments, polynucleotides, and/or compositions of the invention.Type: GrantFiled: April 12, 2018Date of Patent: August 11, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Yee-Peng Chan, Christopher C. Broder
-
Patent number: 10711311Abstract: The present disclosure provides genomic arrangements of the chromosome 3q13 region that are associated with prostate cancer, such as rearrangements between the ZBTB20 and LSAMP genes, including gene fusions between the ZBTB20 gene and the LSAMP gene and deletions spanning both genes. The ZBTB20/LSAMP genomic rearrangement serves as a biomarker for prostate cancer and can be used to stratify prostate cancer based on ethnicity or the severity or aggressiveness of prostate cancer and/or identify a patient for prostate cancer treatment. Another aspect involves discovering that deletions of the PTEN gene are observed predominately in prostate cancer from subjects of Caucasian descent. Also provided are kits for diagnosing and prognosing prostate cancer.Type: GrantFiled: December 30, 2014Date of Patent: July 14, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv K. Srivastava, Albert Dobi, Gyorgy Petrovics, Thomas Werner, Martin Seifert, Matthias Scherf
-
Publication number: 20200188515Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.Type: ApplicationFiled: July 8, 2019Publication date: June 18, 2020Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human ServicesInventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
-
Publication number: 20200157146Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: ApplicationFiled: June 6, 2019Publication date: May 21, 2020Applicants: Board of Regents, The University of Texas System, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
-
Patent number: 10590172Abstract: This invention relates to soluble forms of F glycoprotein from Hendra and Nipah virus and to compositions comprising soluble forms of F glycoprotein from Hendra and Nipah virus. This invention further relates to soluble oligomers of F glycoprotein from Hendra and Nipah virus. This invention also relates to nucleic acids encoding soluble forms of F glycoprotein from Hendra and Nipah virus. This invention also relates to diagnostic and therapeutic methods using the soluble forms of F glycoprotein from Hendra and Nipah virus. Further, this invention relates to antibodies, including neutralizing antibodies, and to vaccines for the prevention, diagnosis and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: August 6, 2018Date of Patent: March 17, 2020Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Yee-peng Chan, Christopher Broder